HomeCompareACRX vs GIS

ACRX vs GIS: Dividend Comparison 2026

ACRX yields 232.56% · GIS yields 6.55%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACRX wins by $293.59M in total portfolio value
10 years
ACRX
ACRX
● Live price
232.56%
Share price
$0.86
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$293.67M
Annual income
$159,094,488.39
Full ACRX calculator →
GIS
GIS
● Live price
6.55%
Share price
$37.11
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79.2K
Annual income
$16,311.42
Full GIS calculator →

Portfolio growth — ACRX vs GIS

📍 ACRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACRXGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACRX + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACRX pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACRX
Annual income on $10K today (after 15% tax)
$19,767.44/yr
After 10yr DRIP, annual income (after tax)
$135,230,315.13/yr
GIS
Annual income on $10K today (after 15% tax)
$556.59/yr
After 10yr DRIP, annual income (after tax)
$13,864.71/yr
At 15% tax rate, ACRX beats the other by $135,216,450.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACRX + GIS for your $10,000?

ACRX: 50%GIS: 50%
100% GIS50/50100% ACRX
Portfolio after 10yr
$146.87M
Annual income
$79,555,399.90/yr
Blended yield
54.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ACRX right now

ACRX
Analyst Ratings
10
Buy
6
Hold
1
Sell
Consensus: Buy
Altman Z
-22.3
Piotroski
4/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.8% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACRX buys
0
GIS buys
0
No recent congressional trades found for ACRX or GIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACRXGIS
Forward yield232.56%6.55%
Annual dividend / share$2.00$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.8%
Portfolio after 10y$293.67M$79.2K
Annual income after 10y$159,094,488.39$16,311.42
Total dividends collected$278.92M$51.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: ACRX vs GIS ($10,000, DRIP)

YearACRX PortfolioACRX Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$33,956$23,255.81$11,504$804.11+$22.5KACRX
2$110,134$73,800.94$13,371$1,061.65+$96.8KACRX
3$341,552$223,709.32$15,723$1,416.15+$325.8KACRX
4$1,013,853$648,391.74$18,735$1,911.16+$995.1KACRX
5$2,883,575$1,798,752.11$22,660$2,613.51+$2.86MACRX
6$7,866,701$4,781,276.29$27,874$3,627.81+$7.84MACRX
7$20,607,870$12,190,500.18$34,947$5,121.52+$20.57MACRX
8$51,895,877$29,845,455.63$44,762$7,369.21+$51.85MACRX
9$125,770,153$70,241,564.71$58,728$10,832.80+$125.71MACRX
10$293,668,552$159,094,488.39$79,151$16,311.42+$293.59MACRX

ACRX vs GIS: Complete Analysis 2026

ACRXStock

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.

Full ACRX Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this ACRX vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACRX vs SCHDACRX vs JEPIACRX vs OACRX vs KOACRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.